Feb 6, 20269:06 AM9:15 AMMain SessionDurable bleed protection for all bleeding subtypes and favorable safety over 5 years (end-of-study) in the Phase 3 HOPE-B trial for persons with severe or moderately severe Haemophilia BFrank LEEBEEK